GTBP - GT Biopharma names Manu Ohri as CFO

GT Biopharma (NASDAQ:GTBP), a clinical-stage immunooncology company, has named Manu Ohri as its Chief Financial Officer (CFO) with immediate effect. Ohri has over 25 years of management, finance and public accounting experience and has served as CFO for multiple public companies. He was previously a management consultant advising companies in sectors including biotech and pharmaceuticals. Michael Breen, GT Biopharma's Executive Chairman, Board of Directors, said: "On behalf of the Board of Directors, we are delighted to name [Ohri] as GT Biopharma's CFO. The company has recently reported positive safety data with first-in-human trials in the advancement of its Tri-Specific Killer Engager (TriKE) development program. This important milestone and proof-of-concept, builds substantial momentum as we progress towards clinical trials with GTB-3650, the Company's second-generation TriKE. [Ohri's] deep experience as CFO for publicly listed companies will play an integral role in the management of the Company's finances and bridging communications with the

For further details see:

GT Biopharma names Manu Ohri as CFO